223 related articles for article (PubMed ID: 27636560)
21. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
[No Abstract] [Full Text] [Related]
22. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
23. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.
Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA
Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475
[TBL] [Abstract][Full Text] [Related]
24. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
Chassagnon G; Hubert D; Fajac I; Burgel PR; Revel MP;
Eur Respir J; 2016 Jul; 48(1):249-52. PubMed ID: 27230445
[No Abstract] [Full Text] [Related]
25. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
26. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
[No Abstract] [Full Text] [Related]
27. Mutation-specific cystic fibrosis treatments on verge of approval.
Dolgin E
Nat Med; 2011 Apr; 17(4):396-7. PubMed ID: 21475213
[No Abstract] [Full Text] [Related]
28. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
Kaiser J
Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
[No Abstract] [Full Text] [Related]
29. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
30. Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X.
Pallin M; Daley CP
J Cyst Fibros; 2020 Jan; 19(1):e3-e4. PubMed ID: 31771899
[No Abstract] [Full Text] [Related]
31. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
Dryden C; Wilkinson J; Young D; Brooker RJ;
Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
[TBL] [Abstract][Full Text] [Related]
32. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
[TBL] [Abstract][Full Text] [Related]
33. [Causal therapy is available].
Meißner T
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
[No Abstract] [Full Text] [Related]
34. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
35. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
36. A safety evaluation of ivacaftor for the treatment of cystic fibrosis.
McColley SA
Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005
[TBL] [Abstract][Full Text] [Related]
37. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
38. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
39. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
40. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]